Recently, Demis Hassabis, one of the founders of Google, revealed in an interview that his company Isomorphic Labs plans to begin a clinical trial for a drug developed using artificial intelligence (AI) by the end of the year. This news has drawn significant attention, particularly regarding its potential applications in oncology, cardiovascular diseases, and neurodegenerative disorders. Image credit: Image generated by AI, image licensed from Midjourney Isomorphic.

In a recent podcast, DeepMind co-founder Demis Hassabis shared his views on the current state of artificial intelligence development. He believes that the capabilities of AI are overly emphasized and exaggerated by the public, leading to some noise. The public's understanding of the significance of AI's future is an outlandish experience. Hassabis expressed surprise at the ability of AI models to infer real-world information based solely on language learning. He noted that many individuals and startups claim functionalities that current technology cannot deliver, referring to these as 'crazy ideas.' Hassabis believes that the long-term potential of AI...

Demis Hassabis, head of Google AI, believes that the development of artificial intelligence poses a threat to humanity similar to that of climate change, expressing concerns about the potential for uncontrolled superintelligent systems. He emphasized that the risks associated with AI must be taken as seriously as climate change and called for the establishment of an independent body to supervise AI, similar to the Intergovernmental Panel on Climate Change (IPCC). Google, Microsoft, OpenAI, and Anthropic announced the creation of a $10 million AI safety fund aimed at advancing the most capable AIs.